Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 1.88%, with notable gains from constituent stocks such as MicroPort Medical (00853) up 8.63%, and Stone Pharmaceutical Group (01093) up 7.40% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 3.00%, marking its third consecutive increase, with a latest price of 1.34 HKD and a weekly cumulative increase of 8.89% [1] - The trading volume for the Hang Seng Biotechnology ETF was active, with a turnover of 34.45% and a transaction value of 161 million HKD, indicating strong market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, growing by 2 million shares over the past week, ranking in the top third among comparable funds [2] - The ETF has seen continuous net inflows over the last three days, with a peak single-day net inflow of 3.83 million HKD, totaling 8.73 million HKD in net inflows [2] Group 3 - Over the past year, the net value of the Hang Seng Biotechnology ETF has increased by 130.59%, ranking 3rd out of 122 QDII equity funds, placing it in the top 2.46% [3] - WuXi Biologics announced the construction of a modular biomanufacturing facility in Singapore, which is part of a strategic collaboration with Pharmadule Morimatsu [3] - The latest report from Zhongyin Securities suggests focusing on three main lines: 1) sectors with stable growth such as medical devices and pharmaceuticals, 2) the CXO sector and medical equipment expected to see a turnaround, and 3) innovative fields related to national medical insurance negotiations [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is highlighted as the only ETF tracking the Hang Seng Biotechnology Index to have received net inflows this year, with the lowest management fee of 0.15% per year among Hong Kong pharmaceutical ETFs [4]

消息面上，同源康医药-B发布公告，于2025年7月28日，公司与配售代理订立配售协议，据此，配售代 理有条件同意作为公司的配售代理，按尽力基准促使承配人按每股配售股份17.01港元的配售价购买923 万股配售股份。 同源康医药-B(02410)涨超3%，截至发稿，涨2.34%，报21.85港元，成交额3234.21万港元。 假设所有配售股份获悉数配售及待完成后，预期配售事项所得款项总额及所得款项净额(经扣除配售佣 金及配售事项的其他相关成本及开支后)将分别约为1.57亿港元及1.55亿港元。按此基准，净发行价将约 为每股股份16.76港元。公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所 得款项净额的约60%，用于现有管线的研发及商业化；配售事项所得款项净额的约30%，用于加强其内 部研发技术能力及扩展其产品组合；及配售事项所得款项净额的约10%，用于营运资金及一般企业用 途。 假设于本公告日期至交割日期期间已发行股份数目并无变动，则配售事项项下的923万股配售股份相当 于经配发及发行配售股份扩大后的已发行H股数目的约2.46%及已发行股份数目的约2.43%。每股配售股 份17.01港 ...

Group 1 - The core point of the news is that Tongyuan Kang Pharmaceutical-B (02410) has announced a placement agreement to issue 9.23 million shares at a price of HKD 17.01 per share, which represents a discount of approximately 19% compared to the last closing price of HKD 21.0 on July 28, 2025 [1][2] - The placement will result in an increase of approximately 2.46% in the total issued H-shares and about 2.43% in the total issued shares of the company [1] - The expected total proceeds from the placement are approximately HKD 157 million, with a net amount of about HKD 155 million after deducting commissions and related costs [2] Group 2 - The company plans to allocate approximately 60% of the net proceeds from the placement for research and commercialization of its existing pipeline [2] - About 30% of the net proceeds will be used to enhance internal research capabilities and expand the product portfolio [2] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國境內，或在刊發或派發本公告屬違法的任何其他 司法權區內刊發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之 邀請或要約。 本公告不構成亦不屬於在美國境內或有關要約屬違法的任何其他司法權區出售證券的任何要約 或招攬購買或認購證券的一部分。本公告所述的本公司股份並無亦不會根據1933年美國證券法 （經修訂）（「美國證券法」）登記，且除非根據美國證券法登記規定進行登記或獲豁免遵守該等登 記規定，否則不得於美國境內提呈發售或出售。本公司無意根據美國證券法登記本公告內所指 之任何證券，或在美國境內進行證券之公開發售。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 根據一般授權配售新H股 配售代理 配售事項 於2025年7月28日（交易時段後），本公司與配售代理訂立配售協 ...

Group 1 - The stock price of Valiant Biotech-B (09887.HK) increased by 113% [1] - The stock price of China Antibody-B (03681.HK) rose by 8.37% [1] - The stock price of Lepu Biopharma-B (02157.HK) went up by 5.64% [1] - The stock price of Tongyuan Kang Pharmaceutical-B (02410.HK) increased by 3.81% [1]

Core Viewpoint - The company announced that three of its self-developed clinical products, TY-302, TY-2699a, and TY-0540, have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) conference, with detailed data to be published in the official ESMO journal, "Annals of Oncology" [1][2]. Group 1: Product Details - TY-302 is a potent, selective oral CDK4/6 inhibitor developed for treating advanced solid tumors such as breast and prostate cancer. It targets CDK4/6 to inhibit the phosphorylation of Rb, preventing cancer cell proliferation. Preclinical studies indicate lower gastrointestinal side effects and more controllable hematological toxicity compared to the leading CDK4/6 inhibitor, palbociclib. Phase I clinical data show significant efficacy and good safety when combined with tamoxifen for HR+/HER2- advanced breast cancer patients [1]. - TY-2699a is a selective CDK7 inhibitor aimed at treating advanced/metastatic solid tumors. Preclinical studies confirm its ability to precisely inhibit cancer cell growth at doses that do not affect normal cells. Initial clinical data demonstrate excellent safety and preliminary efficacy at similar dose levels. The data presented is from a Phase I multicenter monotherapy dose-escalation trial, with ongoing expansion trials for triple-negative breast cancer (TNBC) [2]. - TY-0540 is a selective CDK2 inhibitor intended for treating breast cancer, ovarian cancer, and other solid tumors. It shows strong inhibitory effects on key targets such as CDK2/CycA2 and CDK2/CycE1, while also exhibiting activity against related targets CDK4/CycD1 and CDK6/CycD3. Both preclinical and clinical studies indicate significant inhibitory effects and good safety profiles in various solid tumors, including models resistant to palbociclib. The data presented is from a Phase I multicenter open-label clinical trial, with ongoing Phase Ib/II studies [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願性公告 TY-302、TY-2699a及TY-0540的I期臨床試驗結果獲2025年 歐洲腫瘤內科學會(ESMO)大會以壁報形式收錄 浙江同源康醫藥股份有限公司（「本公司」），連同其附屬公司統稱（「本集團」）自願 刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 本公司董事會（「董事會」）欣然宣佈，公司自主研發的三款臨床產品TY-302、 TY-2699a及TY-0540的I期臨床試驗結果，正式獲2025年歐洲腫瘤內科學會 (ESMO)大會以壁報形式收錄。相關詳細數據將於會議期間展示，並同步發表於 ESMO官方期刊《Annals of Oncology》。 關於CDK4/6抑制劑TY-302 TY-302是一種為治療乳腺癌及前列腺癌等晚期實體瘤而開發的強 ...

Group 1 - The HR+/HER2- breast cancer subtype accounts for approximately 70% of all breast cancer cases globally, with over 2.2 million new cases annually, including about 1.5 million HR+/HER2- cases [1] - Current first-line treatment involves CDK4/6 inhibitors combined with endocrine therapy, but nearly all patients eventually develop resistance, with a median resistance duration of 12-18 months [1] - There are currently no approved targeted therapies for patients who have developed resistance to CDK4/6 inhibitors, and existing second-line options show limited efficacy, with an objective response rate of only 5-10% and median progression-free survival of 3-6 months [1] Group 2 - TY-00540 is a globally leading dual-target CDK2/4 inhibitor that addresses the key mechanism of resistance to CDK4/6 inhibitors by upregulating CDK2 activity [2] - Preclinical studies indicate that TY-00540 demonstrates nanomolar-level inhibitory activity against both CDK2/cyclin E and CDK4/cyclin D1, significantly outperforming single-target CDK4/6 inhibitors or chemotherapy [2] - By simultaneously inhibiting CDK4/6 and CDK2, TY-00540 effectively blocks tumor cell cycle progression, overcoming resistance to CDK4/6 inhibitors [2] Group 3 - The ESMO 2025 conference will present specific data from the Phase I clinical trial of TY-00540, led by Professor Zhang Jian from Fudan University Shanghai Cancer Center [3] - Preliminary results suggest that TY-00540 shows significant anti-tumor activity and manageable safety in patients who have developed resistance to first-line CDK4/6 inhibitors, with objective response rates and disease control rates superior to existing second-line options [3] - The overall safety profile of TY-00540 is favorable, with most treatment-related adverse events being mild to moderate [3]

Core Viewpoint - The announcement by Tongyuan Kang Pharmaceutical regarding the inclusion of three innovative drugs in the upcoming ESMO conference highlights the early clinical value recognized by the international academic community [1] Group 1: Drug Highlights - The CDK2/4 inhibitor TY-00540 shows broad anti-tumor potential, demonstrating strong inhibitory effects on key targets such as CDK2/CycA2 and CDK4/CycD1, with significant efficacy in breast and ovarian cancers [2] - The CDK7 inhibitor TY-2699a exhibits high selectivity for CDK7, with preclinical studies confirming its ability to inhibit cancer cell growth at non-toxic doses to normal cells, showing promising safety and efficacy in early clinical data [3] - The differentiated CDK4/6 inhibitor TY-302 presents a better treatment experience with lower gastrointestinal side effects and manageable hematological toxicity, demonstrating significant efficacy and safety in combination therapy for HR+/HER2- advanced breast cancer [4]

Core Viewpoint - The core product TY-9591 from Sameorigin Pharma made its debut at the ASCO annual meeting, gaining significant attention due to its promising clinical results against the leading lung cancer drug, Osimertinib [1] Group 1: Product Overview - TY-9591 is an oral, irreversible third-generation EGFR inhibitor specifically targeting non-small cell lung cancer (NSCLC) with brain metastases, aiming to challenge Osimertinib's market dominance [2] - It is the first and only drug to show significant improvement over Osimertinib in head-to-head clinical studies for this indication [2] - The drug's pharmacokinetic properties have been optimized by substituting hydrogen atoms in Osimertinib's molecule with deuterium, resulting in a threefold increase in brain tissue concentration compared to Osimertinib [2] Group 2: Clinical Trial Results - In a key Phase II clinical trial, TY-9591 achieved the primary endpoint of intracranial objective response rate (iORR), demonstrating statistically significant and clinically meaningful improvements over Osimertinib across various patient subgroups [3] - The drug is positioned as the fastest-developing candidate for treating NSCLC with brain metastases, potentially reshaping the treatment landscape in China [3] Group 3: Market Potential - The EGFR-TKI market in China has shown significant growth, increasing from 3.1 billion yuan in 2017 to 14.5 billion yuan in 2023, with a compound annual growth rate of 29.3% [4] - The market for third-generation EGFR-TKIs is expected to exceed 20.1 billion yuan by 2027 and 28.4 billion yuan by 2033 [4] - There is a pressing need for innovative treatments for NSCLC with brain metastases, as current standard therapies have limited efficacy, with objective response rates of only 23%-45% [5][6] Group 4: Commercialization Outlook - TY-9591 is set to submit its NDA for conditional approval in China, with the potential to capture significant market share given Osimertinib's current sales exceeding 8 billion yuan [6] - The successful commercialization of TY-9591 is crucial for Sameorigin Pharma's path to profitability [6]